The FDA recently approved Izervay by Astellas (ALPMY), which is a competitor of Apellis’ Syfovre, Stifel tells investors. While the approval for Izervay came early, this was largely anticipated and Stifel believes the GA market is sufficiently large enough for two players. The firm reiterates a Buy rating and $60 price target on the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis downgraded to Neutral from Overweight at JPMorgan
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
- Apellis price target lowered to $70 from $115 at Baird
- Apellis downgraded to Neutral at BofA on wait and see approach to safety issues